BR112013008675A2 - métodos e composições para o tratamento de diabetes e dislipidemia - Google Patents

métodos e composições para o tratamento de diabetes e dislipidemia

Info

Publication number
BR112013008675A2
BR112013008675A2 BR112013008675A BR112013008675A BR112013008675A2 BR 112013008675 A2 BR112013008675 A2 BR 112013008675A2 BR 112013008675 A BR112013008675 A BR 112013008675A BR 112013008675 A BR112013008675 A BR 112013008675A BR 112013008675 A2 BR112013008675 A2 BR 112013008675A2
Authority
BR
Brazil
Prior art keywords
alkyl
cycloalkyl
diabetes
hydroxy
hydrogen
Prior art date
Application number
BR112013008675A
Other languages
English (en)
Inventor
Ish Khanna
Sivaram Pillarisetti
Original Assignee
Kareus Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kareus Therapeutics Sa filed Critical Kareus Therapeutics Sa
Publication of BR112013008675A2 publication Critical patent/BR112013008675A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/27—Polyhydroxylic alcohols containing saturated rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/115—Saturated ethers containing carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/12—Saturated polycyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/15—Saturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Abstract

métodos e composições para o tratamento de diabetes e dislipidemia. a presente invenção refere-se a novos compostos da fórmula i: seus estereoisômeros e/ou sais farmaceuticamente aceitáveis para o tratamento de diabetes e de dislipidemia associada com o diabetes, em que r^ 1^ é selecionado do grupo que consiste em hidróxi, alcóxi, amina, alquila, haloalquila, nhso~ 2r, ou nhcor que r é selecionado de alquila ou cicloalquila, nhr em que r é alquila ou cicloalquila opcionalmente substituída por hidroxi ou alcóxi; e n^ 1^ e n^ 2^ são selecionados independentemente de 0, 1 e 2. pelo menos um de r^ 3^ e r^ 4^e/ou r^ 5^ e r^ 6^ forma um anel cíclico de 3 a 8 átomos de carbono que contêm opcionalmente grupos alquila, heteroátomos, os grupos funcionais tais como o, n, so~ 2~. além disso, quando r^ 3^ ou r^ 5^ e r^ 6^ não formam um anel cíclico, então eles podem ser independentemente selecionados de hidrogênio, alquila, alquila ramificada e cicloalquila. l~ 1~ é uma cadeia alifática linear que contém opcionalmente de 4 a 16 átomos de carbono. a cadeia pode ser opcionalmente substituída uma ou mais vezes por alquila ramificada, cicloalquila ou arila. r^ 2^ é selecionado independentemente de hidrogênio, alcóxi, hidróxi, aquila, haloalquila, cicloalquila, heterocicloalquila, heteroarila, ciano, ou cor^ 7^ em que r^ 7^ é selecionado de hidróxi, alquila, alcóxi, ou amina, nhr, nhso~ 2~r ou nhcor. y^ 1^ é oxigenado ou hidrogênio. y^ 2^ é opcional, em que, quando y^ 2^ é opcional em que, quando y^ 2^ está presente, y^ 1^ e y^ 2^ são hidrogênio. quando y^ 2^ não está presente, y^ 1^ é um grupo carbonila.
BR112013008675A 2010-09-20 2011-09-20 métodos e composições para o tratamento de diabetes e dislipidemia BR112013008675A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38444610P 2010-09-20 2010-09-20
PCT/US2011/052318 WO2012040177A1 (en) 2010-09-20 2011-09-20 Methods and compositions for treatment of diabetes and dyslipidemia

Publications (1)

Publication Number Publication Date
BR112013008675A2 true BR112013008675A2 (pt) 2016-06-21

Family

ID=45818296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008675A BR112013008675A2 (pt) 2010-09-20 2011-09-20 métodos e composições para o tratamento de diabetes e dislipidemia

Country Status (13)

Country Link
US (2) US8623897B2 (pt)
EP (1) EP2618824A4 (pt)
JP (1) JP2013537240A (pt)
KR (1) KR20140009125A (pt)
CN (1) CN103327974A (pt)
AU (1) AU2011305610A1 (pt)
BR (1) BR112013008675A2 (pt)
CA (1) CA2812109A1 (pt)
MX (1) MX2013003078A (pt)
RU (1) RU2013118021A (pt)
SG (1) SG188996A1 (pt)
WO (1) WO2012040177A1 (pt)
ZA (1) ZA201301936B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623897B2 (en) * 2010-09-20 2014-01-07 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
US20140121267A1 (en) * 2011-09-20 2014-05-01 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
ES2861931T3 (es) * 2013-04-04 2021-10-06 Sphaera Pharma Private Ltd Nuevos análogos de epicatequina y polifenoles relacionados
WO2015002818A1 (en) 2013-07-01 2015-01-08 Emory University Treating or preventing nephrogenic diabetes insipidus
AU2015231076B2 (en) * 2014-03-20 2020-05-21 Esperion Therapeutics, Inc. Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
JP6940411B2 (ja) 2015-03-13 2021-09-29 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107118098B (zh) * 2016-02-25 2020-07-14 中国科学院上海药物研究所 一类脂肪酸类化合物、其制备方法及其用途
WO2018144570A1 (en) * 2017-01-31 2018-08-09 Emory University Managing nephrogenic diabetes insipidus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3280169A (en) * 1962-09-18 1966-10-18 Union Carbide Corp Sulfo-substituted aromatic dicarboxylic compounds
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3853951A (en) * 1971-07-14 1974-12-10 American Cyanamid Co Preparation of 9-oxo-13-trans-prostenoic acid esters by alanate addition to cyclopentenone
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4739113A (en) * 1986-05-30 1988-04-19 Merck & Co., Inc. Bis(cyclopropanecarboxamido)alkadienedioic acids as renal dipeptidase inhibitors
JPS63246351A (ja) * 1987-04-02 1988-10-13 Rikagaku Kenkyusho ポリケト−ル系化合物及びその合成法
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
FR2740135B1 (fr) 1995-10-20 1997-12-19 Roussel Uclaf Nouveaux derives de pyrazoles acides, leur procede de preparation, leur application a titre de medicaments, leur nouvelle utilisation et les compositions pharmaceutiques les renfermant
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JPH10273469A (ja) * 1997-02-03 1998-10-13 Takeda Chem Ind Ltd ２環性キノン誘導体、製造法および剤
DE19837620A1 (de) 1997-08-22 1999-02-25 Novartis Ag Organische Verbindungen
SK287996B6 (sk) 1998-03-27 2012-09-03 Janssen Pharmaceutica N. V. Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
US6387897B1 (en) 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6440996B1 (en) 1998-10-07 2002-08-27 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
EP1130469A1 (en) 2000-02-22 2001-09-05 Lucent Technologies Inc. A radiation-sensitive resist material and a process for device fabrication using the same
DE10010430A1 (de) 2000-03-03 2001-09-06 Bayer Ag Substituierte 5-Ethyl-dihydropyridazinone und ihre Verwendung
BRPI0114622B8 (pt) 2000-10-11 2021-05-25 Esperion Therapeutics Inc composto, composição farmacêutica compreendendo o mesmo e uso do referido composto na preparação de composição farmacêutica
WO2002079313A1 (en) 2001-04-02 2002-10-10 Ciba Specialty Chemicals Holding Inc. Stabilized candle wax
US6540795B2 (en) 2001-04-02 2003-04-01 Ciba Specialty Chemicals Corporation Candle wax stabilized with oxazolidines
US6544305B2 (en) 2001-04-02 2003-04-08 Ciba Specialty Chemicals Corporation Candle wax stabilized with piperazinones
US6562084B2 (en) 2001-04-02 2003-05-13 Ciba Specialty Chemicals Corporation Candle wax stabilized with piperazindiones
US6905525B2 (en) 2001-04-02 2005-06-14 Ciba Specialty Chemicals Corporation Candle wax stabilized with piperazinones
US6544304B2 (en) 2001-04-02 2003-04-08 Ciba Specialty Chemicals Corporation Candle wax stabilized with morpholinones
US6547840B2 (en) 2001-04-02 2003-04-15 Ciba Specialty Chemicals Corporation Candle wax stabilized with imidazolidines
CN1326853C (zh) * 2001-10-09 2007-07-18 杏林制药株式会社 4－(2－呋喃甲酰)氨基哌啶、其合成中间体、其制备方法及其作为药物的用途
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
BRPI0318046B8 (pt) 2003-01-23 2021-05-25 Esperion Therapeutics Inc compostos de hidroxila, seu usos, e composições farmacêuticas
AU2003300438A1 (en) 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
CA2549995C (en) * 2003-12-24 2011-11-15 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
JP5345293B2 (ja) 2007-03-29 2013-11-20 株式会社Ａｄｅｋａ 重合性化合物及び重合性組成物
JP5474800B2 (ja) 2007-09-25 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング メソゲンダイマー
US8623897B2 (en) * 2010-09-20 2014-01-07 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia

Also Published As

Publication number Publication date
KR20140009125A (ko) 2014-01-22
RU2013118021A (ru) 2014-10-27
ZA201301936B (en) 2014-05-28
JP2013537240A (ja) 2013-09-30
SG188996A1 (en) 2013-05-31
US8623897B2 (en) 2014-01-07
US20120071528A1 (en) 2012-03-22
EP2618824A4 (en) 2015-05-06
EP2618824A1 (en) 2013-07-31
CA2812109A1 (en) 2012-03-29
AU2011305610A1 (en) 2013-03-14
WO2012040177A1 (en) 2012-03-29
MX2013003078A (es) 2013-09-26
CN103327974A (zh) 2013-09-25
US20140142178A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
BR112013008675A2 (pt) métodos e composições para o tratamento de diabetes e dislipidemia
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
MY165730A (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
TW201129564A (en) Diphenylpyrazolopyridine derivatives, preparation thereof and therapeutic use thereof
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
EA201490726A1 (ru) Фармацевтические соединения для применения в терапии инфекции clostridium difficile
EA201390022A8 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112012033690A2 (pt) sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
BR112012021135A2 (pt) microbicidas
EA201590315A1 (ru) Средства и способ лечения солидных опухолей
AR064198A1 (es) Piperidinilamino piridazinas como antagonistas del receptor de dopamina 2 de rapida disociacion. procesos de obtencion y composiciones farmaceuticas
BR112013005823B8 (pt) Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina
PE20141168A1 (es) Derivados de pirazolidin-3-ona
EA201370251A1 (ru) Производное камптотецина, способ получения такового, фармацевтическая композиция и ее применение
BR112013001862A2 (pt) formulações
PH12014502845B1 (en) Novel cholecystokinin receptor ligands
AR081382A1 (es) Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.